When customers have confidence that a company will behave in their interest even when no one is looking, it reflects the most powerful form of trust. 

Without that bond, people question corporate leadership’s competence, challenge integrity, debate whether customers are truly valued, argue on social media, and worry about security and privacy. The relationship becomes transactional and short-term. 

The corporate instinct is to measure one flaw at a time and fix it — always catching up, never getting ahead. Instead, companies should focus on building durable reputations and ensure their values are reflected in every action they take.  

Trust is easier to build one-on-one. Doctors meet with patients individually, a direct interaction that helps build trust and respect. The same is true for hospitals. For manufacturers, the relationship is equally important — but often more distant. That distance makes trust harder to build, but it also makes genuine long-term commitment more powerful when it’s demonstrated. Trust, earned at that level, becomes self-reinforcing — attracting the best employees, partners, and customers. 

Here are three exceptional examples of what that looks like in practice. 

Novartis developed Coartem, one of the most effective treatments for malaria, and has supplied it to public sector programs in endemic countries at cost or for free since 1999 — delivering well over one billion treatments across sub-Saharan Africa and beyond. Who notices? Governments. The World Health Organization. Global NGOs. The people who benefit from the drug. 

For 27 years, Novartis has been doing the right thing. 

Here’s another example: In 1987, Merck made a landmark decision to donate Mectizan to treat river blindness — indefinitely to everyone who needed it, for as long as necessary. Over 3 billion treatments have been donated since. Dr. Roy Vagelos, the CEO, put it simply: “If we don’t do this, who will?”  The disease-specific drug donation program is now the longest running of its kind. 

When Merck says its mission to save lives isn’t conditional on a patient’s ability to pay, there’s four decades of evidence to support the assertion.  

Finally, Pfizer has been helping uninsured and underinsured patients access its medicines for over 30 years. In 2014, it consolidated that commitment into a unified program — Pfizer RxPathways — helping millions of patients access medications they otherwise couldn’t afford. The message is clear: Pfizer sees patients as people first. 

In each case, the story isn’t about marketing. It’s about values demonstrated through sustained action. 

Every healthcare company has an opportunity to demonstrate genuine commitment to the people they serve. The companies that do it consistently — not in campaigns, but in operations, year after year — are the ones that build trust deep enough to last. 

The question worth asking is: what is your version of that story?